Sellas Life Sciences Group Inc (SLS)
Healthcare
Biotechnology
—
11.20 $
+12.1%
vs. previous close
Closing price · As of: 3. Aug 2026
Sellas Life Sciences Group Inc (SLS) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q1 26), "Operating Cash Flow" came in at -8.8 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -7.6 | -6.9 | -4.8 | -11 | -9.7 | -7.8 | -7.2 | -9.1 | -7.3 | -7.1 | -4.9 | -8.8 | -28 | |
| 0.2 | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.5 | 0.5 | 0.5 | 0.5 | 0.3 | 0.4 | 0.4 | 0.5 | 0.5 | 0.5 | 0.4 | 0.8 | 2.2 | |
| 0.5 | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.6 | 1.7 | 2.7 | -1.8 | -1.6 | -1.2 | -0.9 | -3.9 | -1.4 | -0.9 | 2.1 | -1.4 | -1.6 | |
| 0.0 | 3.0 | 5.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| -2.5 | -3.0 | – | – | – | – | – | – | – | – | – | – | – | |
| 0.0 | 0.0 | 0.0 | – | – | – | – | – | – | – | – | – | – | |
| 0.0 | 0.1 | 3.4 | 27 | 0.4 | 20 | 0.0 | 24 | 4.2 | 26 | 32 | 44 | 107 | |
| -10 | -9.8 | -1.4 | 16 | -9.3 | 12 | -7.1 | 15 | -3.1 | 19 | 27 | 35 | 79 | |
| -7.6 | -9.9 | -10 | -11 | -9.7 | -7.8 | -7.2 | -9.1 | -7.3 | -7.1 | -4.9 | -8.8 | -28 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.